During the quarter the firm launched its ICell8 Single Cell System and made a public offering of stock that raised $17.3 million.
The company reported preliminary Q3 revenue growth of between 52 percent and 68 percent, and raised its revenue guidance for full-year 2015.
The public-private consortium aims to develop and disseminate stem cell-based technologies and assays to study autism spectrum disorder and other mental health diseases.
The microcapillary-based single-cell platform is designed to analyze antibodies but could be used to detect other cell products.
Researchers found that around 13 percent of CLL patients contain at least one partner clone, although the clinical significance of the finding is still unclear.
BD plans to launch a cell sorter for the genomics market over the next six months and to release an automated NGS library prep system in early 2016.
BD plans to pair Cellular Research's highly multiplexed gene expression technology with its flow cytometry platforms.
The company also significantly reduced its full-year 2015 revenue guidance, and noted that it has initiated organizational changes to address underlying issues.
Qiagen believes it has gained access to a relatively simple and inexpensive technology to bolster its offerings in the growing single-cell molecular biology market.
The company continues to expect its single-cell analysis platform will launch by year-end.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.